TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03603119
Drug: Dexamethasone, ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 8mg of dexamethasone i.v. after anaesthesia induction and 4 mg of ondansetron i.v. 30 minutes prior to the end of surgery.
Study: NCT02499120
Drug: palbociclib
Normalized name: Palbociclib
DrugBank: Palbociclib (DB09073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Palbociclib will be supplied as capsules containing 75 mg, 100 mg, or 125 mg equivalents of palbociclib free base. Administered with food on Day 1 to Day 21 followed by 7 days off treatment in a 28-day cycle.
Study: NCT02499120
Drug: Cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab injection for IV infusion will be provided in 100 mg/50 mL, single-use vials, and 200 mg/100 mL, single-use vials. In Japan, cetuximab will be provided in 100 mg/20 mL, single-use vials. Administered, 400 mg/m2 initial dose as a 120-minute IV infusion followed by 250 mg/m2 weekly infused over 60 minutes.
Study: NCT01827592
Drug: Elobixibat 10 mg
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 10 mg/day
Study: NCT01827592
Drug: Elobixibat 5 mg
Normalized name: elobixibat
DrugBank: Elobixibat (DB12486)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Elobixibat 5 mg/day
Study: NCT02810275
Drug: Folinic Acid
Normalized name: Folinic acid
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Folinic acid 5 mg, taking in the morning, daily, during four weeks
Study: NCT00065702
Drug: Active liquid remedy
Normalized name: activated charcoal Oral Liquid Product
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01429298
Drug: Hydromorphone
Normalized name: Hydromorphone
DrugBank: Hydromorphone (DB00327)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2 mg IV hydromorphone over to 2-3 minutes
Study: NCT01377636
Drug: Isoproterenol
Normalized name: Isoproterenol
DrugBank: Isoprenaline (DB01064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: patients will receive isoproterenol, have a BIS monitoring device and a modified isolated forearm test (no neuromuscular blockade).
Study: NCT01394341
Drug: Liraglutide
Normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Daily sc. injection, individual dosage
Study: NCT00767598
Drug: phosphodiesterase type 5 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral administration of 20mg vardenafil
Study: NCT00767598
Drug: phosphodiesterase type 5 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral administration of 100mg sildenafil
Study: NCT00767598
Drug: phosphodiesterase type 5 inhibitor
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: single oral administration of 200mg udenafil
Study: NCT00086606
Drug: Xolair (omalizumab)
Normalized name: omalizumab Injection [Xolair]
DrugBank: Omalizumab (DB00043)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Study: NCT01494012
Drug: fludeoxyglucose F 18
Normalized name: FLUDEOXYGLUCOSE F 18
DrugBank: Fludeoxyglucose (18F) (DB09502)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Undergo FDG-PET/CT
Study: NCT01719159
Drug: Rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: 25 mg rituximab is injected intrathecally via an Ommaya reservoir once a week for 3 weeks. Patients are then followed for one year.
Study: NCT04296578
Drug: Abiraterone Acetate
Normalized name: ABIRATERONE ACETATE
DrugBank: Abiraterone (DB05812)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Standard of Care (SOC) abiraterone (Zytiga) as per package insert. The recommended dose of ZYTIGA is 1,000 mg (four 250 mg tablets) administered orally once daily in combination with prednisone 5 mg administered orally twice daily.
Study: NCT04296578
Drug: Sodium Selenite
Normalized name: Sodium selenite
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 11 mg tablets
Study: NCT04296578
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SOC prednisone 5 mg PO twice daily
Study: NCT00683761
Drug: 131I-TM601
Normalized name: iobenguane (131I)
DrugBank: Iobenguane (DB06704)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: In the first study phase (Dose Escalation), patients will be assigned to treatment to between 2-5 doses of 131I-TM601 treatment at a treatment dose of 1.2 mCi/kg of lean body mass (in scaled dosing, this will amount to 0.024 mg TM601 peptide/kg of lean body mass), once weekly (for between 2-5 weeks, depending upon dose cohort). The maximum amount of administered radioactivity per infusion is 100 mCi.
Study: NCT02150252
Drug: Bu-Yang-Huan-Wu Tang
Normalized name: Ci Wu Jia
DrugBank: Eleuthero (DB14303)
Approvals — FDA: no, EMA: no, PMDA: no
Description: control group,Recruited patients should be received the placebo-BYHWT 3.0 g TID every day for continuously 6 weeks except ordinary medical care; 2) treatment group, the method is identical control group
Study: NCT01750645
Drug: Intradetrusor Injection of Type-A Botulinum Toxin
Normalized name: Botulinum toxin type A
DrugBank: Botulinum toxin type A (DB00083)
Approvals — FDA: no, EMA: yes, PMDA: yes
Study: NCT00684164
Drug: Conivaptan
Normalized name: Conivaptan
DrugBank: Conivaptan (DB00872)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg bolus over 30 min, and then as a 20mg infusion over 24 hours for up to 4 days
Study: NCT00050635
Drug: Sandostatin LAR Depot
Normalized name: SandoSTATIN LAR Depot
DrugBank: Octreotide (DB00104)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00078910
Drug: exisulind
Normalized name: Exisulind
DrugBank: Exisulind (DB06246)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01210482
Drug: Temsirolimus
Normalized name: Temsirolimus
DrugBank: Temsirolimus (DB06287)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: The usual adult dosage is temsirolimus 25 mg once weekly, to be administered via gradual intravenous infusion over 30\~60 minutes. The dosage is to be appropriately reduced according to patients' status.
Study: NCT01223937
Drug: Desmopressin
Normalized name: Desmopressin
DrugBank: Desmopressin (DB00035)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02103660
Drug: Depo-Medroxyprogesterone Acetate
Normalized name: medroxyprogesterone Injection [Depo-Provera]
DrugBank: Progesterone (DB00396)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 150 mg Depo-Medroxyprogesterone Acetate administered every 13 weeks
Study: NCT02103660
Drug: Progestin Contraceptive (Jadelle)
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 implants containing 75 mg of levonorgestrel will be implanted and will last for up to 5 years
Study: NCT00765947
Drug: Aliskiren
Normalized name: Aliskiren
DrugBank: Aliskiren (DB09026)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Aliskiren 150 or 300 mg
Study: NCT00765947
Drug: Hydrochlorothiazide
Normalized name: Hydrochlorothiazide
DrugBank: Hydrochlorothiazide (DB00999)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrochlorothiazide 12.5 or 25 mg
Study: NCT00765947
Drug: Amlodipine
Normalized name: Amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5 or 10 mg
Study: NCT01908309
Drug: Iobitridol 350
Normalized name: iobitridol 350 MG/ML
DrugBank: Iobitridol (DB12407)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01908309
Drug: Iodixanol 320
Normalized name: IODIXANOL 320mgI/ml INJ
DrugBank: Iodixanol (DB01249)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02578849
Drug: L-DOPA
Normalized name: L-dopa
DrugBank: Levodopa (DB01235)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients and healthy controls are recruited to participate in \[11C\]yohimbine scans before and after L-DOPA challenge.
Study: NCT03809234
Drug: Ondansetron 8mg with Saline & Tariquidar
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study: NCT03809234
Drug: Ondansetron 16mg with Saline & Tariquidar
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Each participant will receive two IV infusions of ondansetron, 24 hours apart. In the first and second sessions, respectively, placebo (D5W) or tariquidar (4mg/kg dose in D5W) 22 will be administered IV over 60 minutes. Ondansetron will be diluted in 50mL 0.9% normal saline, and tariquidar will be diluted in 250mL D5W.
Study: NCT02768688
Drug: Dexmedetomidine
Normalized name: Dexmedetomidine
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administering of 0.5-1.0 mcg/kg/hr of dexmedetomidine to ensure subject's loss of consciousness.
Study: NCT00696007
Drug: Gemcitabine and cisplatin
Normalized name: Cisplatin
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Neoadjuvant chemotherapy (gemcitabine and cisplatin) administered before Nephroureterectomy.~Chemotherapy regimen of three cycles of gemcitabine and cisplatin, dosed over a 3 month period Each cycle would consist of gemcitabine and cisplatin on day 1, with two other doses of gemcitabine on day 8 and day 15.~Gemcitabine dosing would be 1,000 mg/m² and cisplatin would be dosed at 70 mg/m²
Study: NCT01027377
Drug: rFVIIIFc
Normalized name: Pegylated rfviii
DrugBank: PEGylated Recombinant Factor VIII (DB16093)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose
Study: NCT00691652
Drug: clofarabine
Normalized name: Clofarabine
DrugBank: Clofarabine (DB00631)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Phase 1 dosing: Initially, 3 patients will be enrolled into a dose level during the dose escalation portion. Level 1: 2mg fixed dose times 14 days for up to 8 cycles. Level 2: 4mg fixed dose times 14 days for up to 8 cycles. Level 3: 6mg fixed dose times 14 days for up to 8 cycles. Phase II dosing: The phase II dose of oral clofarabine will be determined from the phase 1.
Study: NCT00003832
Drug: bromodeoxyuridine
Normalized name: Bromodeoxyuridine
DrugBank: Broxuridine (DB12028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT01888952
Drug: Prednisone
Normalized name: Prednisone
DrugBank: Prednisone (DB00635)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients may receive additional courses of treatment with prednisone (and roflumilast) at the discretion of the investigator if they did not experience unacceptable toxicity and have stable disease or objectively responding disease.
Study: NCT01888952
Drug: Roflumilast
Normalized name: Roflumilast
DrugBank: Roflumilast (DB01656)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Patients may receive additional courses of treatment with roflumilast (and prednisone) at the discretion of the investigator if they did not experience unacceptable toxicity, and have stable disease or objectively responding disease.
Study: NCT03852823
Drug: SG001
Normalized name: Semaglutide
DrugBank: Semaglutide (DB13928)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Phase Ia: Subjects will receive intravenous infusion of SG001 following a sequential dose escalation design (1mg/kg, 3mg/kg and 10mg/kg). Dose limited toxicity (DLT) will be observed within 21 days after the first administration, then subjects can continuously receive SG001 every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial. Phase Ib: Subjects will receive intravenous infusion of SG001 at the dose of 240 mg every 2 weeks until confirmed progression, unacceptable toxicity, or withdrawal from the trial.
Study: NCT00004533
Drug: Adeno-associated virus-CFTR vector
Normalized name: Recombinant adeno-associated virus retinal pigment epithelium gene vector AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01949142
Drug: OTO-201
Normalized name: DB-OTO
DrugBank: DB-OTO (DB18278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single, intratympanic injection
Study: NCT01900847
Drug: Ketamine
Normalized name: Ketamine
DrugBank: Ketamine (DB01221)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 0.3mg/kg ketamine
Study: NCT01900847
Drug: Morphine
Normalized name: Morphine
DrugBank: Morphine (DB00295)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dosage of morphine determined by treating physician
Study: NCT01353391
Drug: Metformin
Normalized name: Metformin
DrugBank: Metformin (DB00331)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: 500 mg daily OD from randomisation for 2 weeks, then 1000mg BID throughout the duration of pregnancy
Study: NCT03939533
Drug: CUTAQUIG
Normalized name: Cutaquig
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Human normal immunoglobulin
Study: NCT01395810
Drug: nonacog beta pegol
Normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose administered intravenously (into the vein) once weekly. Patients will receive instruction on how to treat any bleeding episode they may experience.
Study: NCT01395810
Drug: nonacog beta pegol
Normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose administered intravenously (into the vein). Patients will treat themselves with either a low or a high dose dependent on the severity of the bleeding episode.
Study: NCT01395810
Drug: nonacog beta pegol
Normalized name: Nonacog beta pegol
DrugBank: Nonacog beta pegol (DB13933)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One single dose administered intravenously (into the vein) every second week. Patients will receive instruction on how to treat any bleeding episode they may experience.
Study: NCT00933504
Drug: LACTIC ACID(ND)
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment duration: 6 weeks.
Study: NCT00398216
Drug: DU176b - action is the prevention of venous thromboembolism by the use of a Factor Xa inhibitor
Normalized name: Antisense Oligonucleotide Inhibitor Of The Expression Of Superoxide Dismutase 1 Gene
DrugBank: Tofersen (DB14782)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00570960
Drug: Dextran 70
Normalized name: Dextran 70
DrugBank: Dextran (DB09255)
Approvals — FDA: no, EMA: no, PMDA: no
Description: dextran 70, 1.0 g/kg on days one, two and three
Study: NCT02820519
Drug: Loxapine
Normalized name: Loxapine
DrugBank: Loxapine (DB00408)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Loxapine dose escalation according to tolerability and analgesic efficacy
Study: NCT00536770
Drug: placebo + gemcitabine + erlotinib
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00536770
Drug: Placebo + gemcitabine
DrugBank: Gemcitabine (DB00441)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00536770
Drug: calcitriol + gemcitabine
Normalized name: Calcitriol
DrugBank: Calcitriol (DB00136)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02374424
Drug: GA101_DHAP
Normalized name: DHAP
DrugBank: Dihydroxyacetone phosphate (DB04326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aim of the study is to assess whether the addition of GA101 to DHAP is more promising than standard R-DHAP, as induction therapy before high dose chemotherapy BEAM with ASCT with respect to response.~Scheme of treatment:~* GA101 1000 mg iv day 1, 8, 15 on first cycle (starting from cycle 2, GA101 1000 mg day 1)~* Cisplatin 100 mg/sqm iv day 1 of every cycles in 24-hours infusion~* Cytarabine 2000 mg/sqm in 3-hours infusion every 12 hours iv day 2 of every cycles~* Dexamethasone 40 mg day 1-4 of every cycles~* Pegfilgrastim 6 mg sc single dose 24 hours after the end of chemotherapy or G-CSF from day 4 till stem cell harvest during mobilization's course (II o III cycle GA101-DHAP)~* GA101 1000 mg iv 24 hours before apheresis as purging in vivo during second courses of therapy
Study: NCT00734708
Drug: Trafermin (genetical recombination)
Normalized name: Burosumab (genetical recombination)
DrugBank: Trafermin (DB06244)
Approvals — FDA: no, EMA: no, PMDA: yes
Description: Administered to the bone defect during flap operation
Study: NCT02099253
Drug: Dexmedetomidine 01
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial doses was 1μg/kg, with dose adjustment intervals of 0.05μg/kg.
Study: NCT02099253
Drug: Dexmedetomidine 02
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Initial doses was 0.7μg/kg, with dose adjustment intervals of 0.05μg/kg.
Study: NCT04335084
Drug: Hydroxychloroquine
Normalized name: Hydroxychloroquine
DrugBank: Hydroxychloroquine (DB01611)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prophylaxis treatment for COVID-19
Study: NCT01504139
Drug: LH(r-LH,Luveris, Merck-Serono, Hellerup, Denmark) in the luteal phase
Normalized name: LH
DrugBank: Luteinizing hormone (DB14741)
Approvals — FDA: no, EMA: no, PMDA: no
Description: LH(r-LH, Luveris, Merck-Serono, Hellerup, Denmark) replaces progesterone and estradiol in the luteal phase.
Study: NCT01962948
Drug: paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Given IV
Study: NCT01962948
Drug: ganetespib
Normalized name: Ganetespib
DrugBank: Ganetespib (DB12047)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Given IV
Study: NCT03471143
Drug: adrabetadex (2-Hydroxypropyl-Beta-Cyclodextrin)
Normalized name: Adrabetadex
DrugBank: Adrabetadex (DB15146)
Approvals — FDA: no, EMA: no, PMDA: no
Description: VTS-270 (2-Hydroxypropyl-Beta-Cyclodextrin) will be administered intravenously to specifically target liver disease. In the first phase of the study, dosing frequency will be twice a week with IV adrabetadex (VTS-270) for six weeks for a total of 12 administrations. Subjects will be evaluated at each study visit for evidence of adverse effects.~Doses to be studied are 500, and 1000 mg/kg. Six subjects will be studied at each dose level. Cohort 1: Subjects 1-6, 500 mg/kg Cohort 2: Subjects 7-12, 1000 mg/kg
Study: NCT03679143
Drug: ZSP1273 Low Dose
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ZSP1273 tablets administered orally once daily under fasted or fed condition for 5 Days.
Study: NCT03679143
Drug: ZSP1273 High Dose
Normalized name: HIGH DENSITY POLYETHYLENE
DrugBank: Poly(lactic acid) (DB15037)
Approvals — FDA: no, EMA: no, PMDA: no
Description: ZSP1273 tablets administered orally twice daily for 4 Days and once daily on Day 5 under fasted or fed condition.
Study: NCT03565003
Drug: JAB-3068
Normalized name: JAB-3068
DrugBank: JAB-3068 (DB17131)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg,100 mg
Study: NCT00762034
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Induction therapy 500 milligram per meter squared (mg/m\^2) intravenously (IV) every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Study: NCT00762034
Drug: Pemetrexed
Normalized name: Pemetrexed
DrugBank: Pemetrexed (DB00642)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Maintenance therapy 500 mg/m\^2 IV every 21 days (with bevacizumab) until progressive disease or treatment discontinuation
Study: NCT00762034
Drug: Paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Induction therapy 200 mg/m\^2 IV every 21 days (with carboplatin and bevacizumab) for up to 4 cycles of 21 days
Study: NCT00762034
Drug: Carboplatin
Normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Induction therapy area under the concentration curve (AUC) 6 IV every 21 days for up to 4 cycles of 21 days
Study: NCT00858806
Drug: Imatinib
Normalized name: Imatinib
DrugBank: Imatinib (DB00619)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intermittent Imatinib administration.~* 1 week on / 1 week off for the 1st month(weeks 1-4)~* 2 weeks on / 2 weeks off for the 2nd and the 3rd month (weeks 5-12)~* 1 month on / 1 month off from the 4th month thereafter (weeks 13 on)
Study: NCT00000311
Drug: Buprenorphine
Normalized name: Buprenorphine
DrugBank: Buprenorphine (DB00921)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Medication and Behavioral
Study: NCT00000311
Drug: methadone
Normalized name: Methadone
DrugBank: Methadone (DB00333)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: medication and behavioral
Study: NCT01763827
Drug: Ezetimibe
Normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administered orally once a day
Study: NCT03559751
Drug: Nicotine gum (C)
Normalized name: nicotine Chewing Gum
DrugBank: Nicotine (DB00184)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 4 mg nicotine gum
Study: NCT03457818
Drug: Denosumab 60 mg/ml [Prolia]
Normalized name: denosumab 60 MG/ML [Prolia]
DrugBank: Denosumab (DB06643)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Denosumab 60 mg will be administered subcutaneously in the upper arm at the Baseline and 6 Month Visits
Study: NCT01731327
Drug: tofacitinib modified-release (MR) formulation
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of 11 mg tofacitinib modified-release (MR) administered in a fasting state.
Study: NCT01731327
Drug: tofacitinib modified-release (MR) formulation
DrugBank: Tofacitinib (DB08895)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: A single dose of 22 mg tofacitinib modified-release (MR) administered in a fasting state.
Study: NCT01726465
Drug: Methylprednisolone
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone is a glucocorticoid, which is an adrenocortical steroid. The chemical name for methylprednisolone is pregna-1,4-diene-3,20-dione, 11,17,21-trihydroxy-6-methyl-, (6α,11β)-and the molecular weight is 374.48. It is an analog of naturally occurring glucocorticoid (hydrocortisone and cortisone), which also have salt-retaining properties, are used as replacement therapy in adrenocortical deficiency states. Methylprednisolone is used for their potent anti-inflammatory effects in disorders of many organ systems, it modify the body's immune responses to diverse stimuli. The usual dosage of medication varies in relation to pathology for which is prescribed: normally varies from about 40-60 mg per day up to very high doses of 30 mg/kg bolus as used in spinal cord injury.